Uncertainty over drug regulation and a reluctance by Britain’s health service to use certain pricey modern medicines pose a threat to the country’s respected life sciences sector, the head Swiss drugmaker Roche said on Thursday.
Uncertainty over drug regulation and a reluctance by Britain’s health service to use certain pricey modern medicines pose a threat to the country’s respected life sciences sector, the head Swiss drugmaker Roche said on Thursday.